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Bronchial inflammation is a consistent feature of asthma and its chronicity probably determines disease 
progression. Clinical evaluation of drugs with potential disease-modifying activity requires measurement of their 
effects on the inflammatory and remodelling process using a variety of techniques including bronchial biopsy, and 
analysis of sputum, broncholaveolar lavage, blood, urine and exhaled air. 
Markers of the key components of the inflammatory process, such as the number and activation of T-cells, the 
number of mast cells, cytokine and chemokine release or gene expression, and eosinophil and neutrophil 
recruitment, can be determined in biopsy samples. Biopsies also allow assessment of the integrity and structure of 
the airway epithelium, the thickness of the reticular basement membrane and the numbers and ultrastructure of 
contractile cells. These and other markers may allow differentiation between subtypes of asthma patient according 
to atopic status and will help to distinguish asthma from chronic obstructive pulmonary disease. 
Airway remodelling may be a consequence of chronic bronchial inflammation and is a characteristic of chronic 
asthma, particularly in severe asthma and when there is progressive decline in lung function. There are changes in 
the surface epithelium, reticular basement membrane, bronchial smooth muscle, blood vessels and mucous glands. 
Reliable markers of remodelling need to be identified to improve our ability to evaluate chronic asthma therapy. 
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Introduction 
Eosinophilic inflammation of the airways is common in 
patients with mild and moderately severe asthma and is 
considered to be fundamental to the functional changes 
that characterize the disease (l-3). Persistence of a chronic 
inflammatory response in asthmatic patients is thought to 
initiate the progressive structural change known as ‘airway 
remodelling’, which is probably a major determinant of 
increasing disease severity (4,5). 
Consequently, pharmacotherapy which is demonstrated 
to have an anti-inflammatory property may prevent or slow 
the progress of asthma, rather than simply alleviating 
symptoms. As none of the clinical measures used to 
diagnose asthma can give precise and specific information 
about inflammation, more direct assessment is necessary, 
using techniques such as bronchial biopsy, sputum analysis, 
bronchoalveolar lavage (BAL) and analysis of exhaled air. 
By measuring changes in selected markers, for example 
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recruitment and function of a variety of inflammatory cell 
types, production of inflammatory mediators and expres- 
sion of genes that control synthesis of pro-inflammatory 
proteins or influence the remodelling process, the under- 
lying disease process can be monitored (6,7). 
This overview considers appropriate markers for evalua- 
tion in bronchial biopsies where acute and chronic 
inflammation can be assessed in situ (8). Some of these 
markers may be useful in the future to evaluate the process 
of airway remodelling. It should be recognized, however, 
that interpretation of results from bronchial biopsy analysis 
poses challenges, not least because of the large degree of 
variability that exists between and within patients. 
Variation in asthmatic phenotype 
One factor associated with asthma that can be measured 
simply is atopy. The presence of atopy is associated with 
inflammation, whether or not the patient presents with 
asthma. In one study, biopsies from atopic non-asthmatic 
patients had more activated (EG2+) eosinophils and a 
thicker reticular basement membrane (RBM) than those 
from healthy controls, but these changes were even more 
pronounced in atopic patients with asthma (9). 
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Eosinophilia, whilst variable, is a fundamental feature of 
asthma (10-13) and the associated increase in expression of 
the cytokines interleukin (IL)-4 and IL-13 (which promote 
selective vascular adhesion of these cells) appear to be of 
equal importance in atopic and non-atopic asthma (14). 
Expression of eosinophil chemokines such as eotaxin, 
monocyte chemoattractant protein-3 and RANTES, and 
of IL-4 and IL-5, the T helper-2 (Th2) cytokines, appears to 
be similar in the two patient sub-types (15,16); however, 
expression of granulocyte macrophage colony stimulating 
factor (GM-CSF), which has been shown to be predomi- 
nantly associated with CD68+ macrophages, appears to be 
greater in non-atopic than atopic patients (17). 
In non-atopic and severe intractable asthma, neutrophil 
numbers appear to be significantly increased (l&19). The 
significance of this observation has yet to be clarified; in 
some patients, it may be a functional response to treatment 
with corticosteroids which, in vitro, have been shown to 
down-regulate apoptosis of neutrophils and thus promote 
their longevity (20). 
The amount of the matrix glycoprotein, tenascin, in the 
RBM is greater in chronic and seasonal asthmatic patients 
than in healthy controls, and this elevation in levels appears 
to be more pronounced in patients with chronic disease 
(21). Epithelial integrity is reduced in atopic asthmatic 
patients compared to healthy controls and has been shown 
to be correlated with an increase in airway reactivity (22); 
significant correlations have also been observed between 
TABLE 1. Markers of inflammation: selected examples 
epithelial integrity in atopic patients and the number of 
EG2+ eosinophils and CD4+ T-cells (18). 
Selection of markers of clinical 
inflammation 
Many inflammatory markers can be followed in studies of 
asthmatic subjects; selected examples are listed in Table 1. 
In order to monitor inflammatory changes in atopic 
asthma, a marker of eosinophils is one obvious choice. 
EGI and EG2, markers of eosinophilic cationic protein 
(ECP), are claimed to represent total and activated 
eosinophil counts, respectively. However, the validity of 
this depends on several factors including the way in which 
the cells are fixed and processed (23). Several studies have 
shown that EGZ+ cells may outnumber EGl+ cells; weak 
EG2 positivity may be found in neutrophils, and macro- 
phages may be rendered EG2-positive by ingesting apopto- 
tic eosinophils. These antibodies can be applied to biopsy 
sections, or measurements of EG2+ cells in fluid compart- 
ments can be obtained using flow cytometry. As eosinophils 
tend to cluster, their tissue distribution is not uniform, and 
they are frequently absent from single biopsy sections; 
several sections need to be assessed before a value 
representative of the biopsy is obtained (24,25). If biopsy 
is not practicable, eosinophil markers, e.g. ECF, can also 
be determined in blood, BAL or sputum. In biopsy, 
Tissue Cell Marker 
Biopsies Eosinophil 
Neutrophil 
T lymphocyte 
Activated T lymphocyte 
Macrophage 
Regulatory cytokines 
Chemokines 
Structural changes 
Blood (serum or plasma) 
Sputum 
Urine 
Expired air 
Eosinophil 
Neutrophil 
Cell surface markers 
Eosinophil 
Neutrophil 
Eosinophil 
EG2, EPO 
MPO, HNL 
CD3, CD4, CD8 
CD25 
CD68 
IL-4, IL-5 
IL-8/eotaxin 
Thickened RBM 
Myofibroblast 
Goblet cell 
ECP,EPO 
Numbers in blood 
MPO, HNL 
ICAM-l/VCAM-1 
ECP,EPO 
HNL 
EPX (EDN) 
Nitric oxide 
Hydrogen peroxide 
Carbon monoxide 
Ethane 
ECP, eosinophil cationic protein; EPO, eosinophil peroxidase; EPX, eosinophil protein-X, also known as eosinophil-derived 
neurotoxin (EDN); HNL, human neutrophil lipocalin; ICAM-1, intracellular cell adhesion molecule-l; IL, interleukin; MPO, 
myeloperoxidase; RBM, reticular basement membranel; VCAM, vascular cell adhesion molecule-l. 
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FIG 1. Contribution of inter-subject variability to the total variability of CD45+ cell numbers in bronchial biopsies taken 
from (a) asthma patients and (b) healthy individuals (unpublished data). 
T-lymphocytes and their subsets and cells expressing the 
gene or protein for selected cytokines, e.g. IL-4, IL-5 or IL- 
8, can be counted, and structural changes can be measured 
such as epithelial integrity (22,26), thickness of the 
RBM and its content of tenascin, laminin and ‘collagen’ 
subtypes (21,27,28). Neutrophil markers are appropriate for 
non-atopic asthma, atopic asthma following allergen chal- 
lenge or in severe asthma. Levels of myeloperoxidase (MPO) 
are twice as high in the plasma of non-atopic asthmatic 
patients than in atopic patients and healthy controls 
(unpublished data); this enzyme can also be determined in 
bronchoalveolar lavage fluid. In addition, human neutrophil 
lipocalin (HNL) is a very stable and specific neutrophil 
marker which can be measured in induced sputum samples 
or used as a neutrophil marker in tissues (29). 
By selecting one key marker for each cell type, the total 
number of possible variables monitored can be reduced. 
Importantly, the variability between patients in bronchial 
biopsy studies is a major contributor to total variability in 
the perceived levels of a given marker, as illustrated in 
Fig. 1 for CD45+ T-cells ‘unpublished data’. In studies 
where the variability between patients is expected to be 
high, reinforcement of results may be achieved by following 
two or more linked markers to confirm that a particular 
mechanistic ‘axis’ is affected. An example of such an axis 
would be the numbers of TH2 cells with expression of one 
of the associated cytokines IL-4 or IL-5, and the numbers 
of eosinophils (30). Ideally, the axis chosen should be 
clearly linked with clinical outcomes, e.g. an improvement 
in airway hyper-responsiveness. 
Airway remodelling 
When inflammation in the airways of asthmatic patients 
becomes chronic, a process of inappropriate progressive 
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structural changes known as airway remodelling is often 
present; inflammation and remodelling may be causally 
linked or be separate mechanistic processes (531). The 
production of matrix proteins and growth factors by 
populations of activated inflammatory cells, principally 
eosinophils, may be a first step in the cascade (32). 
Alternatively, a recent study suggests that airway hyper- 
responsiveness (AHR) may predispose to structural 
changes; in four patients who developed asthma 2 years 
after presenting with AHR but no other asthma symptoms, 
comparison of final and baseline biopsy assessments 
showed early increases in subepithelial ‘fibrosis’ and the 
number of CD25+ and CD4+ T cells (33). Evidence is also 
emerging that damage to the bronchial epithelium and a 
disruption of the normal repair mechanism may regulate 
subsequent remodelling (34). The outcomes associated with 
remodelling are thought to include an increase in AHR and 
a reduction in bronchodilator reversibility that probably 
results from reduced elasticity of the bronchus, increased 
smooth muscle mass, mucosal oedema and chronic secre- 
tion of mucus. More studies are needed to characterize the 
sequence of these distinct processes and the effect on them 
of disease-modifying drugs. Investigation of the mechan- 
isms of various structural changes is now beginning. 
RETICULAR BASEMENT MEMBRANE 
(RBM) 
A clearly defined change in asthmatics is thickening of the 
sub-epithelial RBM (22,28). The increased thickness of the 
RBM in asthmatic patients has been shown to be associated 
with increased bronchial hyper-reactivity (35,36), as well as 
with reduced FEVr (4) and an increased rate of exacerba- 
tions (36) but several studies have found no such 
correlations. Investigations of the correlation between 
RBM thickness and disease severity or AHR have also 
produced conflicting results (4,37739). It has been suggested 
that activated eosinophils (EG2+) are involved in the 
genesis of a thickened subepithelial reticular layer, through 
the production of cytokines such as transforming growth 
factor /3 (TGF-/3) (37), but this remains to be validated. 
An additional contribution to the remodelling of extra- 
cellular matrix in chronic airway inflammation stems from 
imbalances between enzymes that degrade matrix proteins 
(matrix metalloproteinases) and endogenous inhibitors of 
these enzymes (tissue inhibitors of metalloproteinases; 
TIMPs). One example is the breakdown of elastin by 
neutrophil elastase; greater activity of this enzyme has been 
reported in asthma patients and a negative correlation has 
been shown with FEVr (40). 
Regulation of the activity of matrix metalloproteinase 
MMP-9 is similarly disrupted in asthma patients; expres- 
sion of the enzyme is greater than that of its tissue inhibitor 
and has been associated with increased RBM thickness and 
reduced FEVi (41). 
VASCULAR CHANGES 
Increased blood flow to a site of injury and inflammation is 
a normal physiological response. Sustained pulmonary 
hyperaemia leads to an increase in the thickness of the 
bronchial wall which narrows the airway lumen (42,43). 
One study of autopsies and resected lung samples from 
asthma patients showed that the density of blood vessels in 
the airway wall was greater than that in control samples 
(44). Recent biopsy studies have demonstrated that asthma 
patients have more vascularized bronchial tissue than 
controls (45,46). A study of the vascularity of the lamina 
propria in asthma patients receiving inhaled corticosteroids 
(ICS) showed no difference in the density of vessels 
compared with patients not on ICS, although the vessel 
density in all patients was correlated with both AHR and 
post-bronchodilator FEVi (47). 
SECRETION OF MUCUS 
Hypersecretion of mucus into the airway lumen in 
asthmatic patients appears to be caused by both submu- 
cosal gland hypertrophy and goblet cell hyperplasia. Goblet 
cell hyperplasia is a prominent phenotypic change in the 
airway epithelium in newly diagnosed asthmatic patients 
(48). After 3 months of inhaled corticosteroid treatment, 
the epithelial structure was shown to be restored to normal 
ciliated epithelium, accompanied by a pronounced reduc- 
tion in the number of inflammatory cells (13). One study 
has reported the proportion by volume of both mucin and 
goblet cells in the epithelium to be three times higher in 
asthmatic patients than in controls (49). This change may 
be driven by increased activity of platelet activating factor 
(PAF) or epidermal growth factor (EGF), both of which 
cause an increase in airway goblet cell number in animal 
models (50,51). EGF immunoreactivity in the epithelium, 
smooth muscle and goblet cells of autopsied bronchi from 
asthma patients has been shown to be greater than that 
from controls with no disease (52). IL-4 and IL-13 levels are 
also known to be raised in asthmatic patients (14) and both 
have been shown to stimulate goblet cell hyperplasia 
(53,54). 
SMOOTH MUSCLE AND THE ROLE OF 
GROWTH FACTORS 
Increased smooth muscle mass contributes to thickening of 
the airway wall. This has been demonstrated by comparing 
autopsy samples from asthma patients and controls with no 
respiratory disease (44,55,56) and by quantifying the effect 
of smooth muscle mass on bronchoconstrictor-provoked 
increases in airway resistance observed in asthma patients 
(57). 
A role for so-called ‘myofibroblasts’ in remodelling was 
first proposed when such cells, defined by immunostaining, 
were shown to be associated with the thickening of the 
RBM and deposition of fibronectin in the bronchial mucosa 
of asthma patients (58). The number of myofibroblasts in 
the mucosa of asthmatic and bronchitic patients was found 
to be correlated with epithelial and submucosal expression 
of TGF-/3 produced by eosinophils and fibroblasts (59). 
Significant correlations have also been found between the 
increased number of myofibroblasts in asthma patients 
compared with controls and the greater thickness of RBM 
containing collagen (types III and V) and tenascin (41). 
Compared with controls, concentrations of TGF-/l are 
raised in asthmatic patients before and 24 h after allergen 
challenge (60). The number of ‘myofibroblasts’ were also 
shown to be markedly increased in asthmatic patients 
following allergen challenge (61), but these cells are likely to 
be distinct from those associated with RBM thickening, 
since they showed ultrastructural similarity to bronchial 
smooth muscle and are suggested to represent de-differ- 
entiated smooth muscle of the synthetic phenotype. The 
changes seen after allergen challenge bear similarity to the 
alterations described in response to vascular injury and 
disease. Another growth factor which can be monitored in 
biopsies is GM-CSF. This cytokine may play a funda- 
mental role in the early stage of remodelling by prolonging 
the survival of eosinophils in the airway of asthmatic 
patients (62). 
Assessment of airway remodelling in 
clinical studies 
The contribution of many processes to the phenomenon of 
airway remodelling in asthma patients complicates the 
selection of a single primary variable that would clearly 
signify the presence and rate of remodelling. Currently, the 
most favoured measurement is that of RBM thickness, but 
assessments of vascularity, myofibroblast numbers and 
phenotypic changes to airway and vascular smooth muscle 
by electron microscopy are becoming key research areas for 
the future. 
Further studies on the structure of the RBM and its 
components in asthmatic patients and healthy controls are 
required to establish which components are significantly 
altered by the disease, and whether asthmatic patients have 
unique components not present in the healthy airway. 
Blood vessels from biopsy samples may be stained using 
markers of endothelium, e.g. CD31, or antibodies to type 
IV collagen which enable the basement membrane of the 
vessel wall to be visualized, so that the number of vessels 
per unit area and their diameter can be measured (45,46). 
Other possible markers include those that measure the 
amounts of mucus-secreting tissue, i.e. the ratio of serous to 
mucous acini, gland size or goblet cell numbers in biopsy 
samples; analysis of mucin gene expression will also be 
important in the future (63,64). Once markers of remodel- 
ling have been clearly identified, the next challenge is to 
show that alterations in these markers are associated with 
changes in long-term clinical outcome. 
Conclusion 
The clinical presentation of asthma and the immunopathol- 
ogy of airway inflammation in asthma have been well 
characterized. The inflammatory mechanisms responsible 
for the involvement of T-cells, eosinophil infiltration. TH2 
cytokine expression and chemokine expression by inflam- 
matory and structural cells can be studied directly in 
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asthma patients by analysing bronchial biopsies. Variability 
of markers within the lung, airway wall and between 
patients, however, may reduce the reliability of estimates, 
and adequate sampling and careful application of quanti- 
tative technique are required. Possible distinctions between 
inflammation in atopic and non-atopic or in mild and 
severe asthma can be explored by employing specific 
markers such as HNL and MPO for neutrophils, and 
EG2 and ECP for eosinophils. 
The field of chronic pulmonary inflammation is now 
being more intensively studied. Although the process of 
inappropriate airway remodelling is not yet understood, 
many of the contributing pathologies are now recognized 
and progress is beginning to be made in identifying 
potential markers that may be followed in long-term 
studies to discover more specific and effective treatments 
for chronic asthma in all its forms. 
References 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic 
inflammation in asthma. N Engl J Med 1990; 323: 
1033-1039. 
Busse WW, Calhoun WF, Sedgwick JD. Mechanism of 
airway inflammation in asthma. Am Rev Respir Dis 
1993; 147: S2CS24. 
Jeffery PK. Structural and inflammatory changes in 
COPD: a comparison with asthma. Thorax 1998; 53: 
1299136. 
Chetta A, Foresi A, Del Denno M, Bertorelli G, Pesci 
A, Olivieri D. Airways remodelling is a distinctive 
feature of asthma and is related to severity of disease. 
Chest 1997; 111: 852-857. 
Bousquet J, Jeffery PK, Busse WW, Johnson M, 
Vignola AM. Asthma. From bronchoconstriction to 
airways inflammation and remodeling. Am J Respir 
Crit Care Med 2000; 161: 1720-1745. 
Adelroth E. How to measure airway inflammation: 
bronchoalveolar lavage and airway biopsies. Can 
Respir J 1998; 5 (Suppl. A): A188A21. 
Jeffery PK, Bousquet J. Methods for assessment of 
airways inflammation. Eur Respir J 1998; 11 (Suppl. 
26): Sl-S58. 
Jeffery PK. Bronchial biopsies and airway inflamma- 
tion. Eur Respir J 1996; 9: 1583-1587. 
Djukanovic R, Lai CKW, Wilson JW, et al. Bronchial 
mucosal manifestations of atopy: a comparison of 
markers of inflammation between atopic asthmatics, 
atopic nonasthmatics and healthy controls. Eur Respir 
J 1992; 5: 538-544. 
Gleich GJ, Motojima S, Frigas E, Kephart GM, 
Fujisawa T, Kravis LP. The eosinophilic leukocyte 
and the pathology of fatal bronchial asthma: evidence 
for pathologic heterogeneity. J Allergy Clin Immunol 
1987; 80: 412415. 
Azzawi M, Bradley B, Jeffery PK, et al. Identification 
of activated T lymphocytes and eosinophils in bron- 
chial biopsies in stable atopic asthma. Am Rev Respir 
Dis 1990; 142: 140771413. 
S14 P. K. JEFFERY ETAL 
12. Azzawi M, Johnston PW, Majumdar S, Kay AB, 
Jeffery PK. T lymphocytes and activated eosinophils in 
asthma and cystic fibrosis. Am Rev Respir Dis 1992; 
145: 1477-1482. 
13. Laitinen LA, Laitinen A, Haahtela T. A comparative 
study of the effects of an inhaled corticosteroid, 
budesonide, and a &agonist, terbutaline, on airway 
inflammation in newly diagnosed asthma: a rando- 
mized, double-blind, parallel-group controlled trial. 
J Allergy Clin Immunol 1992; 90: 3242. 
14. Humbert M, Durham SR, Kimmitt P, et al. Elevated 
expression of messenger ribonucleic acid encoding IL- 
13 in the bronchial mucosa of atopic and nonatopic 
subjects with asthma. J Allergy Clin Immunol 1997; 99: 
657-665. 
15. Humbert M, Yung S, Corrigan C, et al. Bronchial 
mucosal expression of the genes encoding chemokines 
RANTES and MCP-3 in symptomatic atopic and 
nonatopic asthmatics: relationship to the eosinophil- 
active cytokines interleukin (IL)-5, granulocyte macro- 
phage-colony-stimulating factor, and IL-3. Am J Respir 
Cell Mel Biol 1997; 16: 1-8. 
16. Ying S, Meng Q, Zeibecoglou K, et al. Eosinophil 
chemotactic chemokines (eotaxin, eotaxin-2, 
RANTES, monocyte chemoattractant protein-3 
(MCP-3), and MCP-4), and C-C chemokine receptor 
3 expression in bronchial biopsies from atopic and 
nonatopic (intrinsic) asthmatics. J Immunol 1999; 163: 
6321-6329. 
17. Kotsimbos AT, Humbert M, Minshall E, et al. 
Upregulation of alpha GM-CSF-receptor in nonatopic 
asthma but not in atopic asthma. J Allergy Clin 
Immunol 1997; 99: 666-672. 
18. Amin K. The relationship between inflammation and 
structural changes in the airways of the lower and 
upper respiratory tract [dissertation]. Comprehensive 
summaries of Uppsala dissertations from the Faculty 
of Medicine 932. Acta Universitatis Upsaliensis, 2000. 
19. Wenzel SE, Schwartz LB, Langmack EL, et al. 
Evidence that severe asthma can be divided pathologi- 
cally into two inflammatory subtypes with distinct 
physiologic and clinical characteristics. Am J Respir 
Crit Care Med 1999; 160: 1001-1008. 
20. Meagher LC, Cousin JM, Seckl JR, Haslett C. 
Opposing effects of glucocorticoids on the rate of 
apoptosis in neutrophilic and eosinophilic granulo- 
cytes. J Immunol 1996; 156: 4422-4428. 
21. Laitinen A, Altraja A, K%mpe M, Linden M, Virtanen 
I, Laitinen LA. Tenascin is increased in airway base- 
ment membrane of asthmatics and decreased by an 
inhaled steroid. Am J Respir Crit Care Med 1997; 156: 
951-958. 
22. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay 
AB. Bronchial biopsies in asthma. An ultrastructural, 
quantitative study and correlation with hyperreactivity. 
Am Rev Respir Dis 1989; 140: 1745-1753. 
23. Nakajima H, Loegering DA, Kita H, Kephart GM, 
Gleich GJ. Reactivity of monoclonal antibodies EGl 
and EG2 with eosinophils and their granule proteins. 
J Leukoc Biol 1999; 66: 447-454. 
24. Sont JK, Willems LNA, Evertse CE, Hooijer R, Sterk 
PJ, van Krieken JHJM. Repeatability of measures of 
inflammatory cell number in bronchial biopsies in 
atopic asthma. Eur Respir J 1997; 10: 2602-2608. 
25. Sullivan P, Stephens D, Ansari T, Costello J, Jeffery 
PK. Variation in the measurements of basement 
membrane thickness and inflammatory cell number in 
bronchial biopsies. Eur Respir J 1998; 12: 81 l-815. 
26. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela 
T. Damage of the airway epithelium and bronchial 
reactivity in patients with asthma. Am Rev Respir Dis 
1985; 131: 599-606. 
27. Altraja A, Laitinen A, Virtanen I, et al. Expression of 
laminins in the airways in various types of asthmatic 
patients: a morphometric study. Am J Respir Cell Mel 
Biol 1996; 15: 482488. 
28. Roche WR, Beasley R, Williams JH, Holgate ST. 
Subepithelial fibrosis in the bronchi of asthmatic. 
Lancet 1989; i: 520-524. 
29. Betsuyaku T, Nishimura M, Takeyabu K, et al. 
Netutrophil granule proteins in bronchoalveolar lavage 
fluid from subjects with subclinical emphysema. Am J 
Respir Crit Care Med 1999; 159: 1985-1991. 
30. Robinson DS, Hamid Q, Ying S, et al. Predominant 
TH2-like bronchoalveolar T-lymphocyte population in 
atopic asthma. N Engl J Med 1992; 326: 298-304. 
31. Laitinen A, Karjalainen E-M, Altraja A, Laitinen LA. 
Histopathologic features of early and progressive 
asthma. J Allergy Clin immunol2000: 105: S509-S513. 
32. Calhoun WJ, Sedgwick J, Busse WW. The role of 
eosinophils in the pathophysiology of asthma. Ann N Y 
Acad Sci 1991; 629: 62-72. 
33. Laprise C, Laviolette M, Boutet M, Boulet LP. 
Asymptomatic airway hyperresponsiveness: relation- 
ships with airway inflammation and remodelling. Eur 
Respir J 1999; 14: 63-73. 
34. Holgate ST, Lackie PM, Davies DE, Roche WR, Walls 
AF. The bronchial epithelium as a key regulator of 
airway inflammation and remodelling in asthma. Clin 
Exp Allergy 1999; 29 (Suppl. 2): 90-95. 
35. Boulet LP, Laviolette M, Turcotte H, et al. Bronchial 
subepithelial fibrosis correlates with airway responsive- 
ness to methacholine. Chest 1997; 112: 45-52. 
36. Hoshino M, Nakamura Y, Sim JJ. Expression of 
growth factors and remodelling of the airway wall in 
bronchial asthma. Thorax 1998; 53: 21-27. 
37. Minshall EM, Leung DY, Martin RJ, et al. Eosinophil- 
associated TGF-beta 1 mRNA expression and airways 
fibrosis in bronchial asthma. Am J Respir Cell Mel Biol 
1997; 17: 326333. 
38. Chu HW, Halliday JL, Martin RJ, Leung DYM, 
Szefler SJ, Wenzel SE. Collagen deposition in large 
airways may not differentiate severe asthma from 
milder forms of the disease. Am J Respir Crit Care 
Med 1998; 158: 1936-1944. 
39. van Krieken JHJM, Evertse CE, Hooijer R, Willems 
LNA, Sterk PJ. Relationship between the inflammatory 
infiltrate in bronchial biopsy specimens and clinical 
severity of asthma in patients treated with inhaled 
steroids. Thorax 1996; 51: 496-502. 
AIRWAYINFLAMMATIONANDREMODELLING 515 
40. Vignola AM, Bonanno A, Mirabella A, et al. Increased 
levels of elastase and alphal-antitrypsin in sputum of 
asthmatic patients. Am J Respir Crit Care Med 1998; 
157: 505-511. 
41. Hoshino M, Nakamura Y, Sim J, Shimojo 5, Isogai S. 
Bronchial subepithelial fibrosis and expression of 
matrix metalloproteinase-9 in asthmatic airway inflam- 
mation. J Allergy Clin Immunol 1998; 102: 7833788. 
42. Mariassy AT, Gazeroglu H, Wanner A. Morphometry 
of the subepithelial circulation in sheep airways. Am 
Rev Respir Dis 1991; 143: 162-166. 
43. Mitzner W, Wagner E, Brown RH. Is asthma a 
vascular disorder? Chest 1995; 107: S97-S102. 
44. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, 
Hogg JC. Small airways dimensions in asthma and in 
chronic obstructive pulmonary disease. Am Rev Respir 
Dis 1993; 148: 1220-1225. 
45. Li X, Wilson JW. Increased vascularity of the bronchial 
mucosa in mild asthma. Am J Respiv Crit Cave Med 
1997; 156: 229-233. 
46. Vrugt B, Wilson S, Bron A, Holgate ST, Djukanovic R, 
Aalbers R. Bronchial angiogenesis in severe gluco- 
corticoid-dependent asthma. Eur Respir J 2000; 15: 
1014-1021. 
47. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, 
Walters EH. Vascularity in asthmatic airways: relation 
to inhaled steroid dose. Thorax 1999; 54: 289-295. 
48. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal 
inflammation even in patients with newly diagnosed 
asthma. Am Rev Respir Dis 1993; 147: 697-704. 
49. Ordofiez CL, Khashayar R, Ferrando RE, Wong HH, 
Hyde DM, Fahy JV. Increased goblet cell mucin 
content in mild and moderate asthma [abstract]. Am 
J Respir Crit Care Med 1998; 157: A392. 
50. Lou YP, Takeyamma K, Grattan KM, et al. Platelet- 
activating factor induces goblet cell hyperplasia and 
mucin gene expression in airways. Am J Respir Crit 
Care Med 1998; 157: 192771934. 
51. Takeyama K, Dabbagh K, Lee HM, et al. Epidermal 
growth factor system regulates mucin production in 
airways. Proc Nat1 Acad Sci USA 1999; 96: 3081-3086. 
52. Amishima M, Munakata M, Nasuhara Y, et al. 
Expression of epidermal growth factor and epidermal 
growth factor receptor immunoreactivity in the asth- 
matic human airway. Am J Respir Crit Cave Med 1998; 
157: 1907-1912. 
53. Temann UA, Prasad B, Gallup MW, et al. A novel role 
for murine IL-4 in vivo: induction of MUCSAC gene 
expression and mucin hypersecretion. Am J Respir Cell 
Mol Biol 1997; 16: 471478. 
54. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin- 
13: central mediator of allergic asthma. Science 1998; 
282: 2258-226 1. 
55. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri 
LM. Quantitative structural analysis of peripheral 
airways and arteries in sudden fatal asthma. Am Rev 
Respir Dis 1991; 143: 138-143. 
56. Carroll N, Elliot J, Morton A, James A. The structure 
of large and small airways in nonfatal and fatal asthma. 
Am Rev Respir Dis 1993; 147: 405410. 
57. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare 
PD. Functional significance of increased airway 
smooth muscle in asthma and COPD. J Appl Physiol 
1993; 74: 2771-2781. 
58. Brewster CE, Howarth PH, Djukanovic R, Wilson J, 
Holgate ST, Roche WR. Myofibroblasts and sub- 
epithelialfibrosis in bronchial asthma. Am J Respir Cell 
Mol Biol 1990; 3: 507-511. 
59. Vignola AM, Chanez P, Chiappara G, et al. Trans- 
forming growth factor-beta expression in mucosal 
biopsies in asthma and chronic bronchitis. Am J Respir 
Cri Care Med 1997; 156: 591-599. 
60. Redington AE, Madden J, Frew AJ, et al. Transform- 
ing growth factor-beta 1 in asthma. Measurement in 
bronchoalveolar lavage fluid. Am J Respir Crit Cave 
Med 1997; 156: 642647. 
61. Gizycki MJ, Adelroth E, Rogers AV, O’Byrne PM, 
Jeffery PK. Myofibroblast involvement in the allergen- 
induced late response in mild atopic asthma. Am 
J Respir Cell Mol Biol 1997; 16: 664-673. 
62. Park CS, Choi YS. Ki SY, et al. Granulocyte 
macrophage colony-stimulating factor is the main 
cytokine enhancing survival of eosinophils in asthmatic 
airways. Eur Respir J 1998; 12: 872-878. 
63. Jeffery PK, Li D. Airway mucosa: secretory cells, 
mucus and mucin genes. Eur Respir J 1997; 10: 
1655-1662. 
64. Li D, Wang D, Majumdar S, et al. Localization and 
up-regulation of mucin (MUC2) gene expression in 
human nasal biopsies of patients with cystic fibrosis. 
J Pathol 1997; 181: 305-310. 
